{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Dey J"],"pubmed_abstract":["Enterococcus faecium is an emerging ESKAPE bacterium that is capable of causing severe public health complications in humans. There are currently no licensed treatments or vaccinations to combat the deadly pathogen. We aimed to design a potent and novel prophylactic chimeric vaccine against E. faecium through an immunoinformatics approach The antigenic Penicillin-binding protein 5 (PBP 5) protein was selected to identify B and T cell epitopes, followed by conservancy analysis, population coverage, physiochemical assessment, secondary and tertiary structural analysis. Using various immunoinformatics methods and tools, two linear B-cell epitopes, five CTL epitopes, and two HTL epitopes were finally selected for vaccine development. The constructed vaccine was determined to be highly immunoge"],"journal":["Gut pathogens"],"pagination":["21"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9137449"],"repository":["biostudies-literature"],"pubmed_title":["Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium."],"pmcid":["PMC9137449"],"pubmed_authors":["Suar M","Jain P","Misra N","Patro S","Mahapatra SR","Raj TK","Tiwari A","Kaur T","Dey J"],"additional_accession":[]},"is_claimable":false,"name":"Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium.","description":"Enterococcus faecium is an emerging ESKAPE bacterium that is capable of causing severe public health complications in humans. There are currently no licensed treatments or vaccinations to combat the deadly pathogen. We aimed to design a potent and novel prophylactic chimeric vaccine against E. faecium through an immunoinformatics approach The antigenic Penicillin-binding protein 5 (PBP 5) protein was selected to identify B and T cell epitopes, followed by conservancy analysis, population coverage, physiochemical assessment, secondary and tertiary structural analysis. Using various immunoinformatics methods and tools, two linear B-cell epitopes, five CTL epitopes, and two HTL epitopes were finally selected for vaccine development. The constructed vaccine was determined to be highly immunoge","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-06-18T04:58:23.559Z","creation":"2025-04-25T18:11:41.948Z"},"accession":"S-EPMC9137449","cross_references":{"pubmed":["35624464"],"doi":["10.1186/s13099-022-00495-z"]}}